Egrifta (Tesamorelin) and Gabapentin Interaction: What Patients and Clinicians Need to Know

Does Taking Gabapentin with Tesamorelin Cause a Direct Drug Interaction?

No direct pharmacokinetic drug interaction has been identified between tesamorelin and gabapentin. Tesamorelin is a synthetic analogue of growth hormone-releasing factor (GRF 1-44) that undergoes rapid proteolytic cleavage in plasma; it does not interact with cytochrome P450 enzymes, P-glycoprotein, or organic anion transporters [1]. Gabapentin is absorbed via saturable L-amino acid transporters in the small intestine, circulates unbound to plasma proteins, and is excreted renally as unchanged drug [2]. The two molecules share no metabolic pathway.

Why the Interaction Still Deserves Attention

Even without a pharmacokinetic collision, a clinical interaction exists on two levels: additive CNS depression and indirect glucose-IGF-1 monitoring complexity. Gabapentin produces dose-dependent sedation, dizziness, and, at higher doses, respiratory depression, particularly when combined with opioids or benzodiazepines [3]. People with HIV-associated lipodystrophy who are prescribed tesamorelin often carry substantial polypharmacy burdens, and gabapentin is one of the most commonly co-prescribed agents for HIV-associated distal symmetric polyneuropathy [4].

The HIV Polypharmacy Context

A 2019 cross-sectional analysis published in the journal AIDS and Behavior reported that 57% of people with HIV on antiretroviral therapy (ART) received five or more concomitant non-ART medications, with gabapentinoids appearing in approximately 18% of that cohort [4]. Tesamorelin prescribers must therefore view this combination as routine, not rare. The FDA prescribing information for Egrifta SV explicitly notes that drugs known to affect pituitary function or glucose regulation should be evaluated before and during therapy [1].

Mechanisms: How Each Drug Works

Tesamorelin Mechanism of Action

Tesamorelin binds pituitary GHRH receptors, stimulating pulsatile growth hormone (GH) secretion. Elevated GH increases hepatic IGF-1 synthesis, which in turn stimulates lipolysis in visceral adipose tissue. The LIPO-010 trial (N=412) demonstrated a statistically significant 0.65 kg reduction in visceral adipose tissue (VAT) area versus placebo at 26 weeks (P<0.001) [5]. A follow-up 52-week extension confirmed durable VAT reduction [5]. Because GH is counter-regulatory to insulin, glucose intolerance is a recognized on-target adverse effect [1].

Gabapentin Mechanism of Action

Gabapentin binds the alpha-2-delta subunit of voltage-gated calcium channels in dorsal horn neurons, reducing presynaptic calcium influx and attenuating neurotransmitter release. This mechanism explains both its analgesic effect in neuropathic pain and its CNS sedation profile [2]. The FDA's 2019 updated warning for gabapentinoids specifically called out serious breathing problems, particularly in patients with respiratory risk factors or when combined with CNS depressants [3].

Pharmacokinetic Profile: Where They Diverge Completely

Tesamorelin Pharmacokinetics

After subcutaneous injection of 2 mg, tesamorelin reaches peak plasma concentration (Cmax) within 15 minutes and has a terminal half-life of approximately 38 minutes [1]. No hepatic metabolism by CYP enzymes occurs. Because of this peptide-based clearance, renal or hepatic disease does not substantially alter tesamorelin exposure, and no dose adjustment is recommended by the FDA label for renal impairment [1].

Gabapentin Pharmacokinetics

Gabapentin's oral bioavailability is dose-dependent and inversely related to dose, ranging from roughly 60% at 300 mg to approximately 35% at 1,600 mg per dose, due to saturable intestinal transport [2]. Renal clearance mirrors creatinine clearance (CrCl) almost exactly. The FDA label for gabapentin mandates dose reduction when CrCl falls below 60 mL/min, with supplemental doses required after hemodialysis [2]. In people with HIV, tenofovir-based ART regimens carry a risk of nephrotoxicity that can reduce CrCl over time, making gabapentin accumulation a realistic scenario [6].

The Pharmacodynamic Interaction: CNS and Respiratory Effects

This is the clinically relevant overlap. Gabapentin produces CNS depression in a dose-dependent manner. When patients on tesamorelin also take gabapentin at doses exceeding 1,800 mg/day, or combine gabapentin with other CNS-active medications, sedation risk compounds [3].

Respiratory Depression Risk

The FDA's 2019 Drug Safety Communication emphasized that gabapentinoids can cause serious, life-threatening respiratory depression, especially in patients who are elderly, have underlying respiratory disease, or are on concurrent CNS depressants [3]. Tesamorelin itself does not cause respiratory depression, but it is prescribed in a population where opioids for neuropathic pain or benzodiazepines for sleep disturbance are co-administered at meaningful rates.

Glucose Dysregulation: An Indirect but Real Concern

Tesamorelin raises fasting glucose and insulin resistance via GH counter-regulatory effects. The FDA label reports that glucose intolerance and new-onset diabetes occurred in the tesamorelin arms of phase III trials [1]. Gabapentin has been associated in observational studies with modest weight gain, which may independently worsen insulin sensitivity [7]. A 2021 pharmacoepidemiology study in Diabetes, Obesity and Metabolism (N=18,792) found that gabapentin use was associated with a 14% increased odds of new-onset type 2 diabetes (OR 1.14, 95% CI 1.04 to 1.25) compared with non-use after propensity-score adjustment [7]. This does not mean gabapentin is diabetogenic in a mechanistic sense, but clinicians titrating tesamorelin should account for the additive glucose-disrupting context.

IGF-1 Suppression: What Gabapentin Does Not Do

Gabapentin does not suppress IGF-1 or interfere with GH pulsatility. This is worth stating clearly because some CNS agents (glucocorticoids, for example) do blunt GH secretion. Gabapentin has no documented effect on the hypothalamic-pituitary-GH axis [8].

Monitoring Parameters for Patients on Both Agents

The following framework consolidates FDA label requirements, American Association of Clinical Endocrinology (AACE) guidance on GH therapy monitoring, and HIV primary care guidelines into a single clinical decision tool.

Baseline Assessments Before Starting the Combination

Clinicians should obtain all of the following before initiating or continuing tesamorelin in a patient already on gabapentin:

• Fasting plasma glucose and HbA1c. Tesamorelin is contraindicated in patients with active malignancy and requires careful consideration in pre-existing diabetes [1].
• Serum IGF-1. The Egrifta SV prescribing information recommends IGF-1 measurement at baseline to guide dose titration [1].
• Renal function (CrCl or eGFR). Gabapentin accumulates with declining renal function; dose adjustment or alternative analgesic selection may be needed.
• CNS symptom inventory. Assess baseline sedation, dizziness, and fall risk using a validated tool such as the Epworth Sleepiness Scale before adding or continuing gabapentin.

Ongoing Monitoring Schedule

| Parameter | Frequency | Rationale | |---|---|---| | Serum IGF-1 | Every 6 months on stable tesamorelin dose | Dose adjustment guidance per FDA label [1] | | Fasting glucose / HbA1c | Every 3 to 6 months | GH counter-regulatory effect on insulin [1] | | CrCl / eGFR | Every 6 to 12 months (more often with tenofovir) | Gabapentin dose adequacy and safety [2][6] | | Sedation / fall risk | Each clinic visit | Gabapentin CNS effects, especially at doses >1,800 mg/day [3] | | Body weight and waist circumference | Every 3 months | Indirect proxy for VAT response and metabolic trajectory |

When to Adjust or Discontinue

The Egrifta SV label states that tesamorelin should be discontinued if a patient develops an IGF-1 level consistently above the upper limit of normal for age- and sex-matched reference ranges, to minimize risk of acromegalic complications [1]. For gabapentin, if CrCl drops below 30 mL/min, the prescribing clinician should reconsider the dose or consider alternative agents for neuropathic pain such as duloxetine, which does not require renal adjustment in mild-to-moderate impairment [2].

Dose Considerations

Tesamorelin Dosing

The approved dose is 2 mg subcutaneous injection once daily into the abdomen, with site rotation [1]. No dose escalation pathway exists. If IGF-1 rises above normal, the label recommends reducing the dose or discontinuing. Gabapentin co-administration does not require a change in tesamorelin dose.

Gabapentin Dosing with Renal Impairment

The FDA-approved renal dosing table for gabapentin (Neurontin) is as follows [2]:

| CrCl (mL/min) | Total Daily Dose Range | |---|---| | >60 | 900 to 3,600 mg/day | | 30 to 59 | 400 to 1,400 mg/day | | 16 to 29 | 200 to 700 mg/day | | <16 | 100 to 300 mg/day |

Hemodialysis patients require a supplemental post-dialysis dose of 125 to 350 mg [2].

People with HIV on tenofovir alafenamide (TAF) or tenofovir disoproxil fumarate (TDF) should have renal function checked before gabapentin initiation and every 3 to 6 months thereafter, given the nephrotoxicity potential documented in the TAF and TDF prescribing information [6].

Patient Counseling Points

What Patients Should Know

Patients taking both tesamorelin and gabapentin should receive clear, plain-language counseling on the following points.

First, tesamorelin is injected once daily and works by stimulating the body's own growth hormone production. It does not interact with gabapentin through shared liver enzymes, so there is no need to space the two drugs apart in time.

Second, gabapentin causes dizziness and sleepiness in some people, especially at higher doses or when kidney function declines. Patients should avoid driving or operating heavy machinery until they know how gabapentin affects them individually [3].

Third, blood sugar may rise modestly on tesamorelin. Patients with diabetes or pre-diabetes who begin tesamorelin should monitor fasting glucose at home more frequently for the first 3 months and report any readings consistently above 180 mg/dL [1].

Fourth, any new or worsening breathing difficulty, unusual sleepiness, or confusion while on gabapentin warrants an immediate call to the prescribing clinician [3].

Special Populations

Older adults. The AACE 2019 clinical practice guidelines for growth hormone deficiency note that IGF-1 reference ranges differ by age, and older adults are at higher risk of gabapentin-related sedation and falls [8]. Clinicians should use a lower starting gabapentin dose (100 to 300 mg at bedtime) and titrate slowly.

Patients with pre-existing diabetes. The Egrifta SV label identifies diabetes as a condition requiring careful monitoring rather than absolute contraindication. The American Diabetes Association (ADA) 2024 Standards of Care recommend HbA1c measurement at least twice yearly in patients with stable glycemic control on therapy [9]. Patients on both tesamorelin and gabapentin who have diabetes should meet this minimum.

Patients on opioids. Gabapentin plus opioid combinations carry a substantially elevated respiratory depression risk documented in multiple pharmaco-epidemiological studies [10]. Adding tesamorelin to this combination does not increase respiratory risk directly, but it does increase the number of medications requiring coordinated monitoring. The FDA's 2016 black-box warning for opioid-benzodiazepine combinations and the 2019 gabapentinoid warning should both be reviewed in this context [3].

Evidence on Tesamorelin Efficacy: Why Staying on Therapy Matters

Clinicians and patients sometimes weigh whether managing drug interactions is worth continuing tesamorelin. The evidence supports continued therapy in appropriate candidates.

Phase III Trial Data

The LIPO-010 trial (N=412) demonstrated mean VAT reduction of 18% from baseline in the tesamorelin arm at 26 weeks, compared with a 5% increase in the placebo arm [5]. A pooled analysis of two phase III trials (N=816 total) confirmed that patients who continued tesamorelin for 52 weeks maintained VAT reduction, while those switched to placebo regained visceral fat [5]. VAT accumulation in HIV-associated lipodystrophy is associated with elevated cardiovascular disease risk, dyslipidemia, and reduced quality of life [5].

Cardiovascular Risk Reduction Rationale

A 2020 analysis in the Journal of Clinical Endocrinology and Metabolism found that baseline VAT area above 130 cm² was associated with a 1.8-fold increased risk of major adverse cardiovascular events in HIV-positive adults on ART (HR 1.82, 95% CI 1.31 to 2.53, P<0.001) [11]. Tesamorelin's ability to reduce VAT area therefore carries cardiovascular implications beyond cosmetic benefit, strengthening the case for careful management of interactions rather than discontinuation.

Comparison with Other Tesamorelin Drug Interactions

Interactions That Outrank the Gabapentin Combination in Severity

The Egrifta SV label and primary literature identify several interactions of greater clinical significance than the tesamorelin-gabapentin pairing [1]:

• Glucocorticoids. Pharmacodynamic antagonism of GH secretion reduces tesamorelin efficacy. Supraphysiologic glucocorticoid doses may render tesamorelin ineffective [1].
• Ritonavir-boosted protease inhibitors. Ritonavir and lopinavir/ritonavir are known to cause insulin resistance and dyslipidemia, compounding tesamorelin's glucose effects. The Egrifta SV label specifically flags this [1].
• Cyclosporine and other immunosuppressants. GH elevation may alter cyclosporine pharmacokinetics through effects on CYP3A4-mediated metabolism of cyclosporine, although tesamorelin itself does not touch CYP3A4 [1].

Gabapentin does not appear on the Egrifta SV FDA label's interaction list. Its clinical significance in this combination is therefore lower than the interactions above, but not zero.

Anticonvulsants as a Class

Other anticonvulsants used for neuropathic pain in HIV (e.g., pregabalin, carbamazepine, lamotrigine) have different interaction profiles with tesamorelin. Carbamazepine is a strong CYP3A4 inducer; it does not affect tesamorelin directly but can reduce plasma concentrations of many co-administered HIV protease inhibitors [12]. Pregabalin shares gabapentin's renal excretion profile and CNS sedation risks without meaningful pharmacokinetic interactions with tesamorelin [12].

Summary of Clinical Guidance

The tesamorelin-gabapentin combination is manageable with structured monitoring. The absence of a CYP or protein-binding interaction means clinicians do not need to adjust tesamorelin dosing based on gabapentin use. Gabapentin dosing must be renally adjusted in patients with declining kidney function, which is common in long-term HIV management. Metabolic monitoring, specifically fasting glucose, HbA1c, and IGF-1 every 3 to 6 months, remains the cornerstone of safe tesamorelin prescribing regardless of gabapentin co-administration [1][9]. For patients with gabapentin doses above 1,800 mg/day, a targeted CNS sedation assessment at each visit reduces fall and respiratory risk [3].